Revive Therapeutics Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (21)

Latest Posts

About This Stock More About This Stock
Marijuana & Psychedelic Compounds-Based Drug Stocks Index Down, Again
Article By: Lorimer Wilson
Sunday, March 6, 2022 11:28 AM EDT
Our index of the 13 companies working on drugs based on marijuana and/or psychedelics declined -6% last week and is now -37% YTD.
In this article: ZYNE, CRBP, RVVTF, ALID, FTRP
Read
Cannabis And Psychedelic Drug Stock Performances Were Mixed Last Week
Article By: Lorimer Wilson
Saturday, September 11, 2021 7:32 AM EDT
The performance of the psychedelic-focused index components substantially outshone the weed stocks.
In this article: RVVTF, MYCOF, FTHWF, ENVB, ALID, AWKNF
Read
Which Psychedelic Drug Stock Category Outperformed This Past Week?
Article By: Lorimer Wilson
Sunday, August 15, 2021 6:00 AM EDT
Which has performed best lately, the Pure-Play Marijuana Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?
In this article: RVVTF, TBPMF, MYCOF, DMTTF
Read
Marijuana Drug Stocks: All You Need To Know
Article By: Lorimer Wilson
Friday, August 13, 2021 4:53 AM EDT
Eight clinical-stage companies are researching the treatment of a wide variety of illnesses using marijuana. Six have market capitalizations between $50M and $500M; two are between $37M-$50M.
In this article: ZYNE, CRBP, RVVTF, TBPMF, MGCLF, ZLDAF, ENVB, ALID
Read
Cannabis-Centric Bio-Pharma Stocks Category Declined Almost 3% This Past Week
Article By: Lorimer Wilson
Sunday, April 25, 2021 3:00 AM EDT
Introducing our new Cannabis-Centric Bio-Pharma Stocks Index of the 13 clinical-stage biopharmaceutical companies involved exclusively in the development of drugs using CBD and THC.
In this article: GWPH, ZYNE, CRBP, VBIO, RVVTF, CNBX, TBPMF, IMLFF, MGCLF, ZLDAF, ARTL, ENVB
Read

Latest Tweets for $RVVTF

No tweets yet!

PARTNER HEADLINES

$RVVTF

Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market
James Hunter 3/25/2021 3:11:59 AM

Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."

1 to 1 of 1 comments